Vincent P J, Garg M K, Singh Y, Bhalla V P, Datta S
Associate Professor (Surgery), Armed Forces Medical College, Pune - 411 040.
Classified Specialist (Medicine) and Endocrinologist, Command Hosnital, (Southern Command) Pune - 411 040.
Med J Armed Forces India. 2001 Jul;57(3):203-6. doi: 10.1016/S0377-1237(01)80043-5. Epub 2011 Jul 21.
Treatment options for Grave's disease include radio-iodine ablation, which is the standard treatment in the USA, antithyroid drug therapy, which is popular in Japan, and surgery, which is commonly employed in Europe and India. There are very few reports about the outcome of surgery in Grave's disease in the Indian setting. Surgery for Grave's disease is an attractive option in under developed countries to cut short prolonged drug treatment, costly follow up and avoid the need for radio-isotope facilities for 1311 ablation. Aim of the present study was to assess the result of subtotal thyroidectomy in 32 cases of Grave's Disease referred for surgery by the endocrinologist in a teaching hospital. Patients were prepared for surgery with Lugol's iodine and propranalol. Subtotal thyroidectomy was performed by a standard technique, which included dissection and exposure of recurrent laryngeal nerves and parathyroid glands. Actual estimation of weight of the remnant gland was not part of the study. Duration of follow up ranged from 6 months to 4 years. 13 of 32 cases were males. Age ranged from 20 to 57 years. There was 1 death in the immediate post-operative period. There were no cases of permanent hypoparathyroidism or recurrent laryngeal nerve palsy. 1 patient developed temporary hypoparathyroidism. 1 patient developed recurrence of hyperthyroidism and 3 cases developed hypothyroidism all within 2 years of surgery. The study has demonstrated the safety and effectiveness of surgery for Grave's Disease in comparison to the reported high incidence of hypothyroidism following radio-iodine therapy and high recurrence rate after anti thyroid drug therapy.
格雷夫斯病的治疗选择包括放射性碘消融(这是美国的标准治疗方法)、抗甲状腺药物治疗(在日本很流行)以及手术(在欧洲和印度普遍采用)。关于印度环境下格雷夫斯病手术结果的报道非常少。在欠发达国家,格雷夫斯病手术是一个有吸引力的选择,可缩短长期药物治疗、昂贵的随访,并避免131碘消融所需的放射性同位素设施。本研究的目的是评估在一家教学医院由内分泌学家转诊进行手术的32例格雷夫斯病患者行甲状腺次全切除术的结果。患者用卢戈氏碘和普萘洛尔进行手术准备。采用标准技术进行甲状腺次全切除术,包括解剖和暴露喉返神经及甲状旁腺。对残留腺体重量的实际估计不是本研究的一部分。随访时间从6个月到4年不等。32例中有13例为男性。年龄范围为20至57岁。术后即刻有1例死亡。没有永久性甲状旁腺功能减退或喉返神经麻痹的病例。1例患者出现暂时性甲状旁腺功能减退。1例患者出现甲状腺功能亢进复发,3例患者在手术后2年内均出现甲状腺功能减退。该研究表明,与放射性碘治疗后报道的高甲状腺功能减退发生率和抗甲状腺药物治疗后的高复发率相比,格雷夫斯病手术具有安全性和有效性。